cerrar
Tagged with China

Traditional Medicines and OTC Products: China
A legal intro to traditional medicines and OTC products in China. Prepared in association with Fangda Partners, one of China’s most prestigious and…

Marketing, Manufacturing, Packaging & Labeling, Advertising:…
A brief overview of the situation regarding marketing, manufacturing, packaging & labeling and advertising within Chinese pharma. Prepared in…

Preclinical and Clinical Trial Requirements: China
The essential requirements for conducting preclinical and clinical trials in China. Prepared in association with Fangda Partners, one of China’s…

Regulatory, Pricing and Reimbursement: China
An intro to the regulatory, pricing and reimbursement scenario for pharmaceuticals in China. Prepared in association with Fangda Partners, one of…

China Pharma News: Fosun Sales up 20%; MNC Price Manoeuvres Lead…
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis,…

China Strives for First-In-Class Drug Innovation with New Patent…
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of…

PharmaBoardroom’s Top 5 Op-Eds in 2021 (So Far)
As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global…

Hong Chow Leaves Roche China for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General…

Hong Kong: HKEX Biotech IPOs in the First Half of 2021
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has…

China Pharma Roundup: Sinopharm Tops Brand Value Rankings;…
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in…

China Enters CAR-T Era with Fosun-Kite Yescarta Approval
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene…

China Pharma News: First CAR-T Approval; AZ & Bayer Take VBP…
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here